This is a preview of subscription content, log in via an institution to check access.
Reference
Wu Q, et al. Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer From the US and Chinese Perspectives. Frontiers in Oncology : 4 Aug 2020. Available from: URL: https://doi.org/10.3389/fonc.2020.01336
Rights and permissions
About this article
Cite this article
Tucatinib not cost effective in metastatic breast cancer in China and US. PharmacoEcon Outcomes News 861, 33 (2020). https://doi.org/10.1007/s40274-020-7115-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7115-8